Popular search terms:
Search Results
25 results found-
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.ca/news -
Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans
https://www.seqirus.ca/news/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans -
Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults
https://www.seqirus.ca/news/canadian-surveys-highlight-flu-ed-with-healthcare-pros-ease-of-access-critical-vaccination-uptake -
The Government of British Columbia has recently announced that this season they will publicly fund FLUAD®, an inactivated, adjuvanted seasonal influenza vaccine indicated for all seniors residing in a community setting.
https://www.seqirus.ca/news/csl-seqirus-ca-gov-of-brit-columbias-decision-make-fluad-publicly-avail-all-brit-columbian-seniors -
Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months
https://www.seqirus.ca/news/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months -
NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age
https://www.seqirus.ca/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children -
Seqirus Announces Health Canada Approval of Expanded Age Indication
https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of-expanded-age-indication -
Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020
https://www.seqirus.ca/news/seqirus-presents-key-insights-on-influenza-vaccines -
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of--first-cell-based-seasonal-influenza-vaccine